The most important biotech chemicals are only valuable when they are reliable.

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...

Abivax has been seen as a prime takeover target, with rumours claiming that several Big Pharma companies are keen to acquire ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Alvotech (ALVO) announced an amendment to its existing credit agreement, securing a new term loan facility of up to $75M. The financing was led by long-term partner GoldenTree Asset Management LP ...